Logo image of EAPI.PA

EUROAPI SASU (EAPI.PA) Stock Price, Forecast & Analysis

Europe - Euronext Paris - EPA:EAPI - FR0014008VX5 - Common Stock

2.15 EUR
-0.11 (-4.87%)
Last: 1/20/2026, 5:29:00 PM

EAPI.PA Key Statistics, Chart & Performance

Key Statistics
Market Cap205.52M
Revenue(TTM)882.80M
Net Income(TTM)-124.30M
Shares95.59M
Float61.77M
52 Week High3.57
52 Week Low2.1
Yearly Dividend0
Dividend Yield0%
EPS(TTM)-1.31
PEN/A
Fwd PEN/A
Earnings (Next)03-03
IPO2022-05-06
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals
EAPI.PA short term performance overview.The bars show the price performance of EAPI.PA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -10 -20 -30

EAPI.PA long term performance overview.The bars show the price performance of EAPI.PA in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of EAPI.PA is 2.15 EUR. In the past month the price decreased by -5.83%. In the past year, price decreased by -27.93%.

EUROAPI SASU / EAPI Daily stock chart

EAPI.PA Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

EAPI.PA Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to EAPI.PA. The financial health of EAPI.PA is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

EAPI.PA Financial Highlights

Over the last trailing twelve months EAPI.PA reported a non-GAAP Earnings per Share(EPS) of -1.31. The EPS increased by 56.8% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -8.62%
ROE -13.04%
Debt/Equity 0.07
Chartmill High Growth Momentum
EPS Q2Q%18.35%
Sales Q2Q%-8.07%
EPS 1Y (TTM)56.8%
Revenue 1Y (TTM)-9.11%

EAPI.PA Forecast & Estimates

13 analysts have analysed EAPI.PA and the average price target is 2.71 EUR. This implies a price increase of 25.96% is expected in the next year compared to the current price of 2.15.

For the next year, analysts expect an EPS growth of 0.35% and a revenue growth -3.72% for EAPI.PA


Analysts
Analysts46.15
Price Target2.71 (26.05%)
EPS Next Y0.35%
Revenue Next Year-3.72%

EAPI.PA Ownership

Ownership
Inst Owners36.03%
Ins Owners0.01%
Short Float %N/A
Short RatioN/A

About EAPI.PA

Company Profile

EAPI logo image EUROAPI SA engages in manufacturing and supply of active pharmaceutical ingredient solutions for healthcare companies. The company is headquartered in Paris, Ile-De-France and currently employs 3,428 full-time employees. The company went IPO on 2022-05-06. The firm is engaged in the development, manufacture and supply of active-ingredient solutions to its healthcare partners. The company offers vitamin B12, prostaglandins, oligonucleotides, peptides, corticoids and hormones, anti-infectives, opiates (morphine, codeine, thebaine, etc. ), analgesics, etc. The firm also provides technologies and develops molecules through it’s Contract Development and Manufacturing Organization (CDMO). It’s CDMO services include Tides, Prostaglandins, Particle Engineering, Microbial Fermentation, Small Molecules Synthesis, Steroids and Hormones and Opiates & Controlled Substances. The company has production sites located in France, the United Kingdom, Germany, Italy and Hungary.

Company Info

EUROAPI SASU

15, rue Traversiere

Paris ILE-DE-FRANCE FR

Employees: 3187

EAPI Company Website

EAPI Investor Relations

Phone: 33189206200

EUROAPI SASU / EAPI.PA FAQ

Can you describe the business of EUROAPI SASU?

EUROAPI SA engages in manufacturing and supply of active pharmaceutical ingredient solutions for healthcare companies. The company is headquartered in Paris, Ile-De-France and currently employs 3,428 full-time employees. The company went IPO on 2022-05-06. The firm is engaged in the development, manufacture and supply of active-ingredient solutions to its healthcare partners. The company offers vitamin B12, prostaglandins, oligonucleotides, peptides, corticoids and hormones, anti-infectives, opiates (morphine, codeine, thebaine, etc. ), analgesics, etc. The firm also provides technologies and develops molecules through it’s Contract Development and Manufacturing Organization (CDMO). It’s CDMO services include Tides, Prostaglandins, Particle Engineering, Microbial Fermentation, Small Molecules Synthesis, Steroids and Hormones and Opiates & Controlled Substances. The company has production sites located in France, the United Kingdom, Germany, Italy and Hungary.


What is the stock price of EUROAPI SASU today?

The current stock price of EAPI.PA is 2.15 EUR. The price decreased by -4.87% in the last trading session.


Does EUROAPI SASU pay dividends?

EAPI.PA does not pay a dividend.


How is the ChartMill rating for EUROAPI SASU?

EAPI.PA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.


Which stock exchange lists EAPI stock?

EAPI.PA stock is listed on the Euronext Paris exchange.


What is the GICS sector and industry of EAPI stock?

EUROAPI SASU (EAPI.PA) operates in the Health Care sector and the Pharmaceuticals industry.


What is the market capitalization of EAPI stock?

EUROAPI SASU (EAPI.PA) has a market capitalization of 205.52M EUR. This makes EAPI.PA a Micro Cap stock.